Table 2 Univariate and multivariate logistic regression models of 3-month mortality with calprotectin and other baseline characteristics

Age (per 10-year increase)

2.21 (1.65–2.97)

< 0.001

1.71 (1.05–2.79)

0.033

Sex (female)

2.09 (1.23–3.56)

0.007

1.04 (0.41–2.63)

0.939

Weight (kg)^a

0.25 (0.06–1.03)

0.055

0.60 (0.05–7.03)

0.683

Hypertension

2.95 (1.41–6.18)

0.004

2.70 (0.85–8.53)

0.091

Type 2 diabetes

0.64 (0.34–1.21)

0.168

Dyslipidemia

0.66 (0.39–1.13)

0.131

eGFR < 45 mL/min/1.73 m²

2.56 (1.22–5.37)

0.013

1.40 (0.48–4.10)

0.542

SBP at admission^a (per 10-mmHg increase)

2.35 (0.48–11.48)

0.290

DBP at admission (per 10-mmHg increase)

1.17 (1.00–1.36)

0.048

^b

Serum Glucose (mg/dL)^a

1.97 (0.88–4.44)

0.101

1.79 (0.45–7.18)

0.410

Neutrophil count (_xmm3)^a

3.64 (1.83–7.24)

< 0.001

^b

Lymphocyte count (_xmm3)^a

0.42 (0.24–0.72)

0.002

^b

NLR^a

2.41 (1.63–3.58)

< 0.001

1.43 (0.77–2.63)

0.254

C-reactive protein^a (mg/L)

1.02 (1.01–1.03)

< 0.001

1.09 (0.74–1.61)

0.645

Calprotectin μg/mL^a

4.60 (2.86–7.40)

< 0.001

2.31 (1.13–4.73)

0.022

NIHSS score

 8–14 (vs 0–7)

3.75 (1.60–8.80)

0.002

3.01 (1.02–8.87)

0.046

 > 14 (vs 0–7)

11.86 (5.85–24.05)

< 0.001

6.67 (2.25–19.82)

0.001

ASPECTS ≥ 7

0.08 (0.03-0.24)

< 0.001

0.09 (0.01–0.64)

0.017

Baseline mRS score (vs mRS0)

1.67 (1.17–2.37)

0.004

 mRS 1

1.82 (0.80–4.12)

0.152

 mRS 2

3.07 (1.32–7.17)

0.009

 mRS 3

20.15 (7.81–52.01)

< 0.001

Intravenous thrombolysis

2.33 (1.37–3.98)

0.002

1.53 (0.61–3.82)

0.364

Endovascular treatment

1.49 (0.77–2.89)

0.240

Hemorrhagic transformation

4.04 (2.10–7.77)

< 0.001

1.26 (0.40–3.94)

0.695

Cardioembolic stroke

2.37 (1.38–4.06)

0.002

0.71 (0.31–1.63)

0.413